Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 201 - 220 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10 11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

Lupus Foundation of America Studies Reveal Disparities in Care of Minority Patients and the Role of Primary Care Providers in Lupus Care Management

WASHINGTON, Oct. 21, 2018 /PRNewswire/ -- In two first of their kind research studies, the Lupus Foundation of America (LFA) has identified needs in lupus provider education and care practices for minority patients. Referral and disease management practices vary by the type of doctor a patient... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

DxTerity Announces Presentations from Lupus and Multiple Sclerosis Studies at the 2018 ACR/ARHP Annual Meeting

LOS ANGELES, Oct. 21, 2018 /PRNewswire/ -- DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  DXTERITY DIAGNOSTICS, INC.

Philips unveils new radiation oncology portfolio for a more confident path to treatment at ASTRO 2018

AMSTERDAM and SAN ANTONIO, Oct. 21, 2018 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing its new suite of radiation oncology systems and software at the Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

Varian Unveils New Bravos Afterloader System for Brachytherapy Treatments

PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the Bravos((TM) )afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Varian Medical Systems, Inc.

Varian Outlines Strategy for AI-Driven Multimodality Adaptive Radiotherapy Suite

PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian (NYSE: VAR) shared details of its development work on an artificial intelligence (AI)-driven multimodality adaptive radiotherapy treatment... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Varian Medical Systems, Inc.

Samsung unveils a new ultrasound system 'HERA W10' powered by beamforming technology at ISUOG World Congress 2018

New image reconstruction architecture designed to support easier diagnosis to enhance workflow and user experience with innovative features and ergonomics

Read more ››
By: PR Newswire Association LLC. - 21 Oct 2018

Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress

SAN DIEGO, Oct. 21, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the completed stage 1 safety and efficacy data from the ongoing Phase 1b clinical trial of single agent sitravatinib in patients with certain classes... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  MIRATI THERAPEUTICS INC.

Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology

PRINCETON, N.J., Oct. 21, 2018 /PRNewswire/ -- Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan) and Servier jointly announced today the clinical data from the pivotal Phase III (TAGS) trial evaluating LONSURF(®) (trifluridine/tipiracil, TAS-102) versus placebo... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Taiho Ventures, LLC

Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types

WHIPPANY, N.J., Oct. 21, 2018 /PRNewswire/ -- Bayer and Loxo Oncology, Inc. (Nasdaq: LOXO), today announced updated clinical data for larotrectinib in adult and pediatric patients with TRK fusion cancer across 24 unique tumor types. The update included approximately one year of additional follow-up... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Loxo Oncology, Inc.

PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING

Read more ››
By: Nasdaq / GlobenewsWire - 21 Oct 2018
Related companies:  Galapagos NV

Varian Introduces New ProBeam 360° Proton Therapy System

PALO ALTO, Calif., Oct. 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced its new single-room proton therapy system, ProBeam(®) 360°. With a 30 percent smaller footprint than the previous system, ProBeam 360° offers uncompromised clinical capabilities while reducing vault construction... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Varian Medical Systems, Inc.

Varian Forms FlashForward Consortium to Study Ultra-high Dose Rate Cancer Treatments with Protons

PALO ALTO, Calif., Oct. 20, 2018 /PRNewswire/ -- To expand the encouraging preclinical and translational research already conducted by Varian (NYSE: VAR) and two of its clinical partners, Maryland Proton Treatment Center and Cincinnati Children's/UC Health Proton Therapy Center, on the value... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Varian Medical Systems, Inc.

Bioelectronic medicine treatment effective for lupus, pilot clinical trial shows

CHICAGO, Oct. 20, 2018 /PRNewswire/ -- A bioelectronic medicine device was effective in reducing pain and fatigue in patients with lupus, according to Read more ››

By: PR Newswire Association LLC. - 20 Oct 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone

Read more ››
By: Nasdaq / GlobenewsWire - 20 Oct 2018
Related companies:  Novan, Inc.

Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress

Read more ››
By: Nasdaq / GlobenewsWire - 20 Oct 2018
Related companies:  Adaptimmune Therapeutics plc.

CVSI ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CV Sciences, Inc.; Important Oct. 23 Deadline - CVSI

NEW YORK, Oct. 20, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CV Sciences, Inc. (OTC: CVSI) from June 19, 2017 through August 20, 2018, inclusive (the "Class Period"). The... Read more ››

By: PR Newswire Association LLC. - 20 Oct 2018
Related companies:  CV Sciences Inc.

BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

TEL AVIV, Israel, October 20, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 20 Oct 2018

OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer

Read more ››
By: Nasdaq / GlobenewsWire - 20 Oct 2018
Related companies:  OncoMed Pharmaceuticals, Inc.

Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress

Read more ››
By: Nasdaq / GlobenewsWire - 20 Oct 2018
Related companies:  Dynavax Technologies Corporation

INNATE PHARMA : Phase II results from monalizumab/cetuximab in head and neck cancer at ESMO

Read more ››
By: Nasdaq / GlobenewsWire - 20 Oct 2018
Related companies:  Innate Pharma S.A.
«  1  2  3  4  5  6  7  8  9  10 11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑